Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + tetracycline is a combination of two antibiotics used primarily in the treatment of Helicobacter pylori infection, often as part of a quadruple therapy regimen. Amoxicillin is a penicillin-type, bactericidal antibiotic that interferes with bacterial cell wall synthesis, leading to cell lysis and death during the bacterial multiplication period. Tetracycline is a broad-spectrum, bacteriostatic antibiotic that inhibits protein synthesis by reversibly binding to the 30S ribosomal subunit in bacteria, preventing tRNA attachment and thus blocking peptide chain formation. The combination leverages both mechanisms for enhanced antibacterial activity against H. pylori; however, some evidence suggests potential antagonism between these agents due to their differing actions on bacterial growth phases[2][8]. This regimen is considered an alternative when other therapies are unsuitable or resistance rates are high[2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amoxicillin + tetracycline.